Rhabdomyolysis in prostate cancer--caution in prescribing cyproterone acetate with statins.
Ahamed
E
E
Department of Clinical Oncology, Grampian University Hospitals NHS Trust, Aberdeen, UK. e.ahamed@abdn.ac.uk
Bissett
D
D
D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D017373:Cyproterone Acetate / Q000009:adverse effects* / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012206:Rhabdomyolysis / Q000139:chemically induced*; D019821:Simvastatin / Q000009:adverse effects* / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D000970:Antineoplastic Agents; D017373:Cyproterone Acetate; D019821:Simvastatin